1. 1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-label, phase III study. Lancet Oncol 10: 223-232, 2009.
2. 2. Götze K, Platzbecker U, Giagounidis A, et al. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group. Ann Hematol 89: 841-850, 2010.
3. 3. Higuchi M, Sasaki S, Kawadoko S, et al. Epstein-Barr virus-positive diffuse large B-cell lymphoma following acute myeloid leukemia: a common clonal origin indicated by chromosomal translocation t(3;4)(p25;q21). Int J Hematol 102: 482-487, 2015.
4. 4. Xu X, Hassan A. Extranodal marginal zone lymphoma arising in a patient with chronic myelogenous leukemia on long-term tyrosine kinase inhibitors. Leuk Lymphoma 55: 715-717, 2014.
5. 5. Chim CS, Choi PT, Lee WK, et al. Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide. Ann Hematol 92: 855-857, 2013.